Document is current

Article History

Received: 5 September 2024

Accepted: 17 November 2024

First Online: 20 December 2024

Conflict of interest

: M. Gnant: Personal fees/travel support from Amgen, AstraZeneca, DaiichiSankyo, Eli Lilly, EPG Health (IQVIA), Menarini-Stemline, MSD, Novartis, PierreFabre, Veracyte; an immediate family member is employed by Sandoz. M. Balic: Research Funding, Advisory role, Speakers bureau: AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Pierre Fabre, Roche, Pfizer, Samsung, Menarini. Research Funding, Speakers bureau: Novartis. Research Funding, Advisory role: Seagen. Advisory Role: MSD. Advisory Role, Speakers bureau: Stemline. C.F. Singer: Personal fees, grants and travel support from Amgen, Seagen, AstraZeneca, Daiichi Sankyo, Menarini-Stemline, Novartis, Gilead, Roche and Pfizer. G. Rinnerthaler: Honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche, Seagen, Stemline, BMS; Consulting or Advisory Role: AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Stemline; Speakers bureau: none; Research Funding: none; Patents, Royalties; Travel, Accommodations, Expenses: Amgen, Daiichi Sankyo, Eli Lilly, Gilead, Merck, Pfizer, Roche; Other Relationship: none. G. Pfeiler: Honoraria and grants from Amgen, Seagen, AstraZeneca, Daiichi, Gilead, Roche, Novartis, Pfizer, Menarini, MSD, Accord, Lilly. C. Suppan: Consulting or Advisory Role: Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca, Gilead, Daiichi Sankyo, Pierre Fabre. Speakers bureau: Roche, Novartis, Pfizer, Eli Lilly, Pierre Fabre, Astra Zeneca, Gilead, Daiichi Sankyo. Travel, Accommodations, Expenses: Roche, Novartis, Pfizer, Astellas, AstraZeneca, Daiichi Sankyo, Pierre Fabre. B. Grünberger: Honoraria for advisory role/Lecture honoraria from AstraZeneca, Daiichi, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Servier, Merck, Takeda, Taiho. K. Strasser-Weippl: Congress support from Roche, Pfizer, Novartis, MSD, Lilly. Speaker Fees/Advisory Boards: Roche, Pfizer, Novartis, Lilly, Daiichi, Myriad, MSD, Gilead, Seagen. V. Castagnaviz: Speaking Honoraria: Daiichi Sankyo, AstraZeneca. Advisory board/Consulting Honoraria: Novartis. Travel and conference attendance: Daiichi Sankyo, Gilead, Pierre Fabre, Lilly. S. Heibl: Honoraria, Advisory Board, Congress Support from AstraZeneca, Stemline, Novartis, Lilly, Roche, AbbVie, Takeda, BMS, Daiichi Sankyo, Gilead, Sanofi, GSK, Janssen, MSD. R. Bartsch: Advisory Role: AstraZeneca, Daiichi, Eisai, Eli Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Stemline. Lecture Honoraria: AstraZeneca, BMS, Daiichi, Eisai, Eli Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Stemline. Research Support: Daiichi, MSD, Novartis, Roche.